[go: up one dir, main page]

WO2019214838A1 - Utilisation d'une composition contenant de l'alcool pour améliorer la fonction barrière de la peau - Google Patents

Utilisation d'une composition contenant de l'alcool pour améliorer la fonction barrière de la peau Download PDF

Info

Publication number
WO2019214838A1
WO2019214838A1 PCT/EP2018/086671 EP2018086671W WO2019214838A1 WO 2019214838 A1 WO2019214838 A1 WO 2019214838A1 EP 2018086671 W EP2018086671 W EP 2018086671W WO 2019214838 A1 WO2019214838 A1 WO 2019214838A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
composition
weight
alcohol
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2018/086671
Other languages
English (en)
Inventor
Marie Lodén
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eviderm Institute AB
Original Assignee
Eviderm Institute AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eviderm Institute AB filed Critical Eviderm Institute AB
Publication of WO2019214838A1 publication Critical patent/WO2019214838A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to alcohol-containing compositions for dermal application which compositions also contain urea, and more particularly the use of such compositions for improving the skin barrier function.
  • Alcohol-based disinfectants and biocidal products are regularly used in healthcare and medical care, such as in hospitals and in clinics, to prevent spreading of nosocomial infec- tions and other disinfectant purposes.
  • studies on nurses and other health care personnel show that frequent hand washing and disinfection lead to a high risk of develop- ing skin dryness, fissures and hand eczema.
  • Alcohol-based disinfectants are also perceived by users to be damaging to the skin, which hamper their use. Water, detergents, antimicro- bial agents and low molecular weight alcohols are all known to cause dryness and be irri tants to the skin.
  • ECHA European Chemical Agency
  • ECHA European Chemical Agency
  • Hand disinfection - PT 1 harmonisation of exposure determinants for professional users.
  • composition which could be used as a disinfectant, hav- ing improved skin tolerability and which reduces skin sensitivity towards irritating agents.
  • composition which can be used as a disinfectant, having improved skin tolerability, and reducing skin sensitivity to e.g soaps.
  • the present inventor has surprisingly found that a combination of urea and alcohol when applied to the skin repeatedly may not only counteract the skin irritating effect of the alco- hol, but also improve the barrier function of the skin, also at concentrations of the alcohol which are generally considered in the art to be effective for disinfection, i.e. at concentra- tions of at least 50 % by volume.
  • an alcohol-based composition containing urea can surprisingly be used for improving the barrier function of the skin and reducing its sensitivity to dryness and occurrence of eczema.
  • the skin can be protected during repeated disinfection procedures, and during disinfecting conditions.
  • the inventive use of an alcohol containing composition may thus reduce the risk of developing eczema, especially on the hands, dur ing disinfection routines in e.g. hospitals and clinics. Also, by reducing or even killing off bacteria and yeast present on the skin, any skin- barrier impairing effect from the presence of such bacteria and yeast can be reduced or prevented by the inventive use. Accordingly, the skin barrier function may be improved also from this point of view according to the invention.
  • an alcohol containing composition can enhance the barrier function of skin, and hence render skin more resistant to irritants and allergens, e.g. to chemicals released from bacteria or fungi present on the skin, or to other damaging chemicals in con tact with the skin.
  • the inventive use can generally reduce the risk of developing eczema, especially on the hands, and during treatment of other skin disorders on other body surfaces.
  • the invention relates to the use of a composition containing: 30-96 % by weight of an alcohol selected from the group consisting of ethanol, isopropanol, and n- propanol, or a combination thereof; 0.5-20 % by weight of urea, and water for improving the skin barrier function in a mammal by dermal application of the composition to the skin.
  • the composition used according to the invention additionally contains a hydrolysable carboxylic ester.
  • the ester serves to prevent formation of ammo nia which may result from urea hydrolysis during storage of the urea-containing composi tion.
  • a hydrolysable ester By using a hydrolysable ester, the addition of a carboxylic acid for preventing for mation of ammonia may be avoided. Thereby any possible stinging which may otherwise result from the presence of such added carboxylic acid can be avoided.
  • composition is preferably used in the form of a gel, especially a gel which collapses when applied on the skin, such as a carbomer type of gel.
  • the hydrolysable carboxylic ester may also serve the purpose of stabi lising the gel during storage.
  • the carboxylic ester may also improve the transparency of the gel.
  • the inventive use of the alcohol containing composition may be biocidal, cosmetic, veter inary or medical.
  • the present invention relates to a composition containing: 30-96 % by weight of an alcohol selected from the group consisting of ethanol, isopropa nol, and n-propanol, or a combination thereof; 0.5-20 % by weight of urea, and water, for use in improving the barrier function of the skin by repeated application of the composi tion to a desired area of the skin.
  • the inventive composition may be used for treating atopic dermatitis (AD), for avoiding eczema, for prophylactic treatment of the skin for subsequent exposure of the skin to irri tating substances, or for prolonging the period of time until relapse of eczema.
  • Treatment and prevention of eczema may also be related to the change of skin microflora, where it is known that certain microorganisms may increase sensitivity to eczema (e.g. head and neck dermatitis).
  • the inventive composition can also be used for treatment of other skin disor ders characterized by microorganisms, such as dandruff, which usually involves the yeast Malassezia furfur but also bacteria such as Propionobacterium and Staphylococcus. Fur thermore, other superficial skin infections by Malassezia furfur known as Pityriasis versi color can be treated successfully.
  • the inventive composition could also be used for pre venting asthma, as will be explained below.
  • the invention relates to a method of improving the barrier function of the skin in a mammal, comprising the step of applying repeatedly a composition containing: 30-96 % by weight of an alcohol selected from the group consisting of ethanol, isopropa nol, and n-propanol, or a combination thereof; 0.5-20 % by weight of urea, and, water, to a desired area of the skin of the mammal in which area the barrier function of the skin is to be improved.
  • the composition is preferably applied repeatedly during a day, i.e. preferably at least twice daily.
  • the invention relates to the use of a composition containing: 30-96 % by weight of an alcohol selected from the group consisting of ethanol, isopropanol, and n- propanol, or a combination thereof; 0.5-20 % by weight of urea, and water for disinfection of skin of a mammal, wherein the barrier function of the skin is improved when the com position is applied repeatedly to the skin.
  • biocidal is intended to comprise disinfectant, antiseptic, antibac terial, antimicrobial, antifungal etc.
  • composition could be comple mented accordingly with conventionally used additives, such as disinfectant agents, anti septic agents, antibacterial agents, antimicrobial agents, anti-fungal agents.
  • alcohol-containing compositions can surprisingly be used for improving the barrier function of the skin, measured either as reduced transepi- dermal water loss (TEWL), or, as a reduced sensitivity of the skin, e.g. to a known soap irritant.
  • TEWL transepi- dermal water loss
  • urea in the inventive composition allows for simultaneous exposure of the skin to irritating substances, and hence skin-damaging alcohols can be used in the composition for killing off bacteria on the skin, while at the same time the risk of any possible damage to the skin by such treatment is being reduced.
  • the skin will also be rendered more tolerable to subsequent exposure of the skin to an irritant.
  • SE 511 551 discloses that repeated application of a urea containing composition to the skin can build up a protection against the skin irritation that would otherwise arise upon contact of the skin with an irritating substance, such as a surfactant solution.
  • the invention disclosed therein thus generally relates to the use of a urea containing composition for prophylactic treatment of normal skin in order to prevent irritation.
  • AD is considered a primary disorder related to SC barrier failure with elevated transepi- dermal water loss (TEWL) linked to mutations in the filaggrin gene.
  • TEWL transepi- dermal water loss
  • Another common feature of AD is colonization by Staphylococcus aureus , where the antimicrobial barrier function is compromised.
  • defect barrier function in AD has been suggested to have consequences not only for the development of eczema but also to other conditions such as asthma.
  • the skin barrier itself has been suggested a likely contributor to the devel- opment of contact sensitization, as irritant contact dermatitis is reported to often precede allergic contact dermatitis with onset at lower ages, i.e. shows a similar temporal relation ship clinically as with eczema and asthma.
  • ichthyosis may be linked to the filaggrin gene.
  • the alcohols used in alcohol-based disinfectants are typically ethanol, isopropa- nol, and n-propanol, or a combination thereof.
  • the alcohol con tent is typically between 60 % and 90 % by volume. Once alcohol concentrations drop below 50% by volume, usefulness for disinfection drops sharply without the addition of other biocidal agents.
  • preferred alcohol concentrations in the art are with in 60-80 % by volume. Many institutions use 70 % by volume alcohol blends as standard.
  • the present invention could be used to reduce the irritability of the alcohol in such products too. It is believed that the inventive use serves to make the skin more tight, i.e. less permeable. Therefore, the irritability of the skin to other skin irritating substances could also be re- Jerusalem by the inventive use of the alcohol containing compositions.
  • the alcohol containing composition used according to the invention could include other irritating substances in the formulation in addition to the alcohol, such as e.g. denaturants (e.g. methyl ethyl ketone), quaternary compounds (e.g. benzalkonium chlo- ride, chlorhexidine), and fragrances.
  • denaturants e.g. methyl ethyl ketone
  • quaternary compounds e.g
  • a generally preferred range of alcohol is 50 to 96 % by weight, such as 50 to 90 % by weight, more preferably 60-90 % by weight, typically 60-80 % by weight, such as e.g. 65-75 % by weight.
  • the composition can suitably be formulated so as to exhibit an amount of about 70 % by weight of alcohol, which is slightly above the standard concentration of 70 % by volume as conventionally used in alcohol-based disin fectants.
  • an ethanol content of 60.0 % by weight corresponds to 67.7 % by volume of ethanol
  • 80.0 % by weight corresponds to 85.4 % by volume
  • 70.0 % by weight corresponds to 76.9 % by volume at 20°C.
  • Ethanol is a preferred alcohol for use in the inventive compo sitions, and it is generally preferred that ethanol constitutes the major part of the alcohol- content, preferably at least 85 % by weight, and more preferably at least 90 % by weight of the alcohol content.
  • any other primary alcohols present in the composition in addition to the ethanol, such as any of propanols, and butanols, are merely used for de naturing the ethanol, as may be required under national regulations.
  • alcohol is used at lower concentrations, such as lower than 50 % by weight, if desired, the disinfecting effect could be enhanced by addition of a biocidal agent such as e.g. chlorhexidine.
  • Urea is contained in an amount of from 0.5-20 % by weight in the inventive composition, preferably 1.5-20, more preferred 2-20, and especially preferred 3-10 % by weight, such as e.g. 5 % by weight.
  • the lower limit of 0.5% by weight is believed to be suitable for a composition which is applied very frequent during a day. Accordingly, when formulated as a disinfectant for frequent use during a day, a lower amount of urea may be preferred, such as from 0.5 % by weight, or from 1 % by weight, up to 5 % by weight, e.g. up to 4, or up 3 % by weight.
  • the inventive composition contains a hydrolysable carboxylic ester.
  • Hydrolysable esters that can be used in the invention are in general those listed in US 4 488 989, and more preferably propyl lactate, butyl acetate, ethyl acetate, ethyl lac- tate, ethyl citrate, ethyl glycolate, menthyl lactate, pyroglutamic acid ethyl ester, or a mix ture thereof.
  • preferred esters are the lactates, and an especially preferred ester is ethyl lactate. During hydrolysis the hydrolysable ester will form the corresponding car boxylic acid and alcohol.
  • the carboxylic acid formed will lower the pH and neutralise the ammonia being liberated by the slow hydrolysis of urea.
  • the amount of hydrolysable car boxylic ester should be selected so as to be effective for neutralising the ammonia formed.
  • the amount required for this purpose is generally within a ratio by weight of ester to urea of 1 :5 to 1 :25, depending on the specific ester and the molecular weight thereof.
  • methyl salicylate could be included in certain embodiments of the inventive composition.
  • a gel is formed from the composition used according to the invention, more preferably a gel which collapses on the skin.
  • examples of such gels which collapse on the skin after application thereof are known in the art, and can for example be formed from crosslinked electrolyte-sensitive hydrogels, such as polyacrylic acid (car- bomer), or ammonium acryloyldimethyltaurate/VP copolymer.
  • the collapse of the gel is typically mediated by the action of salt present on the skin.
  • Such gels are consequently sensitive to the presence of salt in the composition, accordingly the amount of salt in the composition should be kept sufficiently low, so as to not break the gel form.
  • the inventive gel may for example be essentially transparent.
  • the inventive composition used contains an effective amount of ammonium acryloyldimethyltaurate/VP copolymer forming a gel.
  • the inventive composition used contains an effective amount of one or more carbomers for forming a gel.
  • the content of salts in the composi- tion must be very low, and the pH should be above about 4, preferably at least 4.5, and more preferably at least 5.
  • a lower pH and/or higher amounts of salts will prevent the car bomer molecules from forming a suitable transparent gel.
  • a generally preferred range of pH is a value from 5-7, e.g. 5-6.
  • the hydrolysable ester can be used for stabilising a pH-sensitive gel against undesired increase in the pH value due to the formation of ammonia from hydrolysis of urea.
  • an improved stability of a carbomer gel can be ob tained.
  • a buffer such as those made of lactic acid or citric acid, is typically used for controlling the pH value of dermal compositions containing urea.
  • a buffer which may typically be provided in the form of a salt, is not required for stabilising the pH in the inventive urea-containing composition.
  • Such buffer salt may otherwise prevent a gel from being formed.
  • a carboxylic acid may typically be used for controlling the pH value of a dermal composition.
  • said ester will provide a reservoir of carboxylic acid, and will provide for pro longed sustained release thereof to the composition.
  • a carboxylic acid does not have to be added as such to the composition for lowering the pH of the composition used according to the invention.
  • salt formation associated with the presence of a substantive amount of added carboxylic acid can be avoided, and also stinging from an added carboxylic acid can be prevented.
  • an acid such as a carboxylic acid, is not added to the inventive composition.
  • acids and buffers are preferably not added to the composition used according to the invention.
  • the inventive composition can be provided for veterinary use, or for human use. For ex- ample, the composition could be used on animals, such as domestic animals or cattle, e.g. dogs, cats, and cows, especially dogs.
  • the in ventive composition may contain an antimicrobial agent that will be deposited on the skin upon application of the composition to the skin.
  • antimicrobial agents are quaternary compounds (e.g. cetrimide, benzalkonium chloride), phenols, halogen releasing agents (e.g. iodine and chlorine compounds), aldehydes (e.g. formaldehyde), heavy met als.
  • Propanediol can also be included in the inventive composition as a humectant, solvent and for antimicrobial purposes, e.g. for antifungal purposes.
  • the inventive composition may contain an antifungal agent, such as e.g. piroctone olamine.
  • an antifungal agent such as e.g. piroctone olamine.
  • Piroctone olamine is believed to be especially useful when the composition is targeting dandruff, e.g. on hairy areas such as the scalp and animals.
  • the acidic carbomer polymer must be neutralised in order to achieve maximum viscosity, and thus to form a gel.
  • piroctone olamine can be used to neutralize the acidic carbomer polymer, and for adjusting the pH of the inventive compositions.
  • the alcohol containing composition can also be used on other areas of the skin of the human body where an antimicrobial effect or disinfection is desired, such as for treating bacteria or fungi in facial skin, such in the T- zone, or in the head and neck area.
  • Niacinamide could be used in the inventive composition to further improve the skin condi tion.
  • the inventive composition used according to the invention can preferably be formulated as an antimicrobial composition for use in repeated disinfection procedures of human skin, especially hands, on hospitals.
  • Other types of gels can also be used, such as gels which are not sensitive to salts, such as for example based on cellulosic ether polymers, e.g. hydroxymethyl, hydroxyethyl, and hydroxypropyl cellulose, and carboxymethylcellulose (CMC).
  • cellulosic ether polymers e.g. hydroxymethyl, hydroxyethyl, and hydroxypropyl cellulose, and carboxymethylcellulose (CMC).
  • CMC carboxymethylcellulose
  • composition used according to the invention is believed to generally improve the re- sistance of the skin, i.e. to irritating substances in bacteria, and in fungi, as well as to de- tergents etc.
  • the inventive composition when formulated so as to be disinfectant, will be able to kill off bacteria, fungi/yeasts and virus present on the treated skin, and to make the treated skin more resistant to irritant substances released from such microorganisms.
  • the inventive composition can be applied to a desired portion of the skin, for improving the barrier function in said portion of the skin.
  • the composition is preferably applied in the form of a gel, especially a collapsible gel.
  • the number of applications of an inventive formulation per day is determined by the desired effects from the formulation, where higher frequencies allow lower concentration of urea, and once daily application require higher concentration of urea to obtain similar daily dosage.
  • the composition is preferably used on hands and forearms of the human body, especially when the composition contains 50 % by weight or more of alcohol.
  • the inventive composition could be provided in a dispenser, e.g. a hand wash or a gel, or as a disposable article, such as a swab, wipe, or rub which is impregnated or soaked with the inventive composition.
  • a dispenser e.g. a hand wash or a gel
  • a disposable article such as a swab, wipe, or rub which is impregnated or soaked with the inventive composition.
  • the compositions of the alcohol gels with urea should preferably not contain non-volatile compounds (e.g. lipids, oils, carbohydrates) which dilute and counteract the effects of urea and potentially act as nutrients to deleterious microorganisms on the skin.
  • inventive effect may not be discernible until after a number of days of re peated applications of the inventive composition. Accordingly, it may take over a week until the inventive effect is obtained. It is believed that the time until the inventive effect is obtained will be reduced with increasing number of daily applications.
  • Healthy skin was treated with a simple alcoholic gel with urea, a complex alcoholic gel with urea, or a plain ethanol gel (placebo/control without urea) twice daily for 18 days on one of the volar forearms (randomized), where the other arm served as untreated control.
  • skin barrier function is measured as transepidermal water loss (TEWL). All percentages of the compositions are given by weight unless oth erwise indicated.
  • About 0.4 g was applied to the skin at each time (i.e. 0.8 g per day), to a surface area of about 50-70 cm 2 .
  • the simple alcoholic gel formulation contained 5% urea, 70% ethanol, 0.8 % carbomer and water to 100%, and pH was adjusted to 5-6 using piroctone olamine.
  • the complex alcohol gel contained 5 % urea, 70% ethanol, 0.8 % carbomer, 1 % niacina- mide, 4 % propanediol and water, adjusted to pH 5-6.
  • the plain placebo gel contained 70% ethanol, 0.8 % carbomer, and water, pH was adjust- ed to 5-6. This gel was tested on 2 healthy individuals in the same randomised study as the other gels of Examples 1 and 2. The results showed increased TEWL and increased sensi tivity to the soap, supporting the findings that alcohol damages the skin and the improve ment noted from the treatment with ethanol-urea gels were attributed to urea and not the excipients in the gel.
  • Table 1 visual evaluation of the degree of irritation in the skin exposed to 1% sodium lauryl sulphate after treatment with the simple ethanol-urea gel of Example 1, the more complex urea gel of Example 2, and a comparative plain ethanol-gel is given.
  • the table gives the number of subjects with the defined scores in treated skin and untreated control skin (within parenthesis) and the percent of the summed scores in the treated area compared to the untreated. The p-value denotes the significance level between the gel and the untreated control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions contenant de l'alcool pour application dermique, en particulier destinées à être utilisées en tant que désinfectants, ayant une tolérabilité améliorée, lesdites compositions contenant également de l'urée. Les compositions décrites améliorent la fonction barrière de la peau.
PCT/EP2018/086671 2018-05-09 2018-12-21 Utilisation d'une composition contenant de l'alcool pour améliorer la fonction barrière de la peau Ceased WO2019214838A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18171474 2018-05-09
EP18171474.2 2018-05-09

Publications (1)

Publication Number Publication Date
WO2019214838A1 true WO2019214838A1 (fr) 2019-11-14

Family

ID=62148173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/086671 Ceased WO2019214838A1 (fr) 2018-05-09 2018-12-21 Utilisation d'une composition contenant de l'alcool pour améliorer la fonction barrière de la peau

Country Status (1)

Country Link
WO (1) WO2019214838A1 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4488989A (en) 1983-11-14 1984-12-18 Lever Brothers Company Aqueous compositions containing urea as a hydrotrope
SE511551C2 (sv) 1994-03-30 1999-10-18 Aco Hud Ab Användning av en ureahaltig komposition för profylaktisk långtidsbehandling av normal hud
US20050196450A1 (en) * 2004-03-04 2005-09-08 Elka Touitou Method and composition for burned skin
US20090018213A1 (en) * 2006-02-09 2009-01-15 Marcia Snyder Antiviral method
WO2011014850A2 (fr) * 2009-07-31 2011-02-03 Nuvo Research Inc. Formulations à usage topique à base d'un eutectique
WO2011079234A2 (fr) * 2009-12-23 2011-06-30 Nuvo Research Inc. Formulation de terbinafine à grande perméation
EP2664327A1 (fr) * 2012-05-14 2013-11-20 Almirall S.A. Compositions pharmaceutiques topiques comprenant du terbinafide et de l'urée
WO2015072910A1 (fr) * 2013-11-14 2015-05-21 Lipidor Ab Compositions topiques pharmaceutiques, cosmétiques et désinfectantes comprenant de la phosphatidylcholine
WO2017055797A1 (fr) * 2015-09-30 2017-04-06 Deb Ip Limited Désinfectant cutané à base d'alcool ayant des propriétés microbicides
US20180104227A1 (en) * 2015-03-28 2018-04-19 Kolmar Korea Nail lacquer composition containing ciclopirox

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4488989A (en) 1983-11-14 1984-12-18 Lever Brothers Company Aqueous compositions containing urea as a hydrotrope
SE511551C2 (sv) 1994-03-30 1999-10-18 Aco Hud Ab Användning av en ureahaltig komposition för profylaktisk långtidsbehandling av normal hud
US20050196450A1 (en) * 2004-03-04 2005-09-08 Elka Touitou Method and composition for burned skin
US20090018213A1 (en) * 2006-02-09 2009-01-15 Marcia Snyder Antiviral method
WO2011014850A2 (fr) * 2009-07-31 2011-02-03 Nuvo Research Inc. Formulations à usage topique à base d'un eutectique
WO2011079234A2 (fr) * 2009-12-23 2011-06-30 Nuvo Research Inc. Formulation de terbinafine à grande perméation
EP2664327A1 (fr) * 2012-05-14 2013-11-20 Almirall S.A. Compositions pharmaceutiques topiques comprenant du terbinafide et de l'urée
WO2015072910A1 (fr) * 2013-11-14 2015-05-21 Lipidor Ab Compositions topiques pharmaceutiques, cosmétiques et désinfectantes comprenant de la phosphatidylcholine
US20180104227A1 (en) * 2015-03-28 2018-04-19 Kolmar Korea Nail lacquer composition containing ciclopirox
WO2017055797A1 (fr) * 2015-09-30 2017-04-06 Deb Ip Limited Désinfectant cutané à base d'alcool ayant des propriétés microbicides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARTNER ET AL.: "Effect on different alcohols on stratum corneum kallikrein 5 and phospholipase A together with epidermal keratinocytes and skin irritation", INT. J. COSMET. SCI., vol. 39, 2017, pages 188 - 196
SCHEUPLEIN; BLANK, J INVEST DERMATOL, vol. 60, 1973, pages 286 - 296

Similar Documents

Publication Publication Date Title
US6805874B1 (en) Method and skin cleansing compositions for dermatological basic treatment
JP5318351B2 (ja) 術前皮膚消毒用の組成物及び方法
JP5788385B2 (ja) 抗菌性組成物
US5716611A (en) Emollient antimicrobial formulations containing povidone iodine
EP2594248B1 (fr) Constituants actifs combinés et leur utilisation
EP2934121B1 (fr) Compositions antimicrobiennes améliorées
US20110076244A1 (en) Surface coatings for skin
US20080015262A1 (en) Pest Treatment Composition
DE69901997T2 (de) Kosmetische oder dermatologische Zusammensetzung enthaltend mindestens ein Alkynylcarbamat und mindestens ein Polyol
DE102007045242A1 (de) Benzaldehyde in kosmetischen oder dermatologischen Zubereitungen
JP2010524866A (ja) 爪障害の治療のための局所殺菌剤
CN102894001A (zh) 一种湿巾用防腐防霉剂组合物及其生产方法
WO2020176697A1 (fr) Compositions repoussant les insectes et leurs procédés de fabrication
EP2196090A1 (fr) Produit de désinfection virucide
AU2020271339B2 (en) Liquid composition for influencing the microbiota on a subject's skin comprising chitosan
WO2001089503A1 (fr) Composition de traitement contre les parasites
US7544366B1 (en) Method and skin cleansing compositions for dermatological basic treatment
WO2019214838A1 (fr) Utilisation d'une composition contenant de l'alcool pour améliorer la fonction barrière de la peau
US9775346B1 (en) Hand sanitizer composition and method of manufacture
CN106794166B (zh) 脂肪酸酯用于改进醇消毒剂的抗微生物效力的用途
DE69623641T2 (de) Topisch anzuwendendes abschäumendes arzneimittel zur behandlung von durch pityrosporum ovale verursachten hauterkrankungen
JP2001278728A (ja) 化粧料
DE102005006104A1 (de) Verschäumbare alkoholische Mittel mit Desinfektions- und Reinigungswirkung auf (Erd)Alkali- Basis und deren Verwendung
DE102020204728A1 (de) Hautdesinfektionsmittel
DE102020111882A1 (de) Ionische Flüssigkeit als Antitranspirant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18826726

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18826726

Country of ref document: EP

Kind code of ref document: A1